What changed: Brain and spinal cord tumours (all types)
Every dated change on the records linked to Brain and spinal cord tumours (all types), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2024 · 2
- 2024Trial resultGBM AGILEGBM AGILE reported
Regorafenib, the first arm, did not improve overall survival in newly diagnosed or recurrent glioblastoma; paxalisib and VAL-083 did not graduate; later arms continue.
- 2024MilestoneVorasidenibVorasidenib approved for IDH-mutant glioma
First targeted drug for grade 2 astrocytoma and oligodendroglioma after surgery (INDIGO trial).
2020 · 1
2017 · 1
2016 · 4
- 2016Trial resultAlliance N0574 (NCCTG N0574)Alliance N0574 (NCCTG N0574) reported
Cognitive deterioration at 3 months 63.
- 2016Trial resultEORTC 22033-26033EORTC 22033-26033 reported
Median progression-free survival 46 (radiotherapy) vs 39 months (temozolomide), no significant difference.
- 2016Trial resultQUARTZQUARTZ reported
Quality-adjusted life-years 46.
- 2016MilestoneBrain and spinal cord tumours (all types)WHO classification adds molecular markers
IDH mutation, 1p/19q codeletion and H3 K27M began to define brain tumour types alongside microscopy; extended in 2021.